Genetron Holdings Limited (GTH)
| Previous close | 1.1600 |
| Open | 1.1800 |
| Bid | 1.1800 x 800 |
| Ask | 1.2400 x 1100 |
| Day's range | 1.1650 - 1.2300 |
| 52-week range | 0.7310 - 4.3000 |
| Volume | |
| Avg. volume | 158,544 |
| Market cap | 111.441M |
| Beta (5Y monthly) | 0.43 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.9010 |
| Earnings date | 27 Mar 2023 - 31 Mar 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 2.92 |
- GlobeNewswire
Genetron Health Regains Compliance With Nasdaq Minimum Bid Price Requirement
BEIJING, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Genetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that the Company had received a notification letter (“Compliance Notice”) from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”), dated Jan
- GlobeNewswire
Genetron Health Announces Receipt of Notification from Nasdaq
BEIJING, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it has received written notification from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) dated October 28, 2022, indicating that fo
- GlobeNewswire
Genetron Health Reports Unaudited Second Quarter 2022 Financial Results
BEIJING, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today reported its unaudited financial results for the second quarter ended June 30, 2022. Recent Business Highlights Received College of American Pathologists (CAP) Accreditation for its laboratory
